-
2
-
-
3042585338
-
Deep vein thrombosis and pulmonary embolism in two cohorts: The longitudinal investigation of thromboembolism etiology
-
DOI 10.1016/j.amjmed.2004.01.018, PII S0002934304001676
-
Cushman M, Tsai AW, White RH, et al. Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology. Am J Med 2004;117:19-25. (Pubitemid 38801482)
-
(2004)
American Journal of Medicine
, vol.117
, Issue.1
, pp. 19-25
-
-
Cushman, M.1
Tsai, A.W.2
White, R.H.3
Heckbert, S.R.4
Rosamond, W.D.5
Enright, P.6
Folsom, A.R.7
-
3
-
-
34147169563
-
Incidence and mortality of venous thrombosis: A population-based study
-
DOI 10.1111/j.1538-7836.2007.02450.x
-
Naess IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, Hammerstrøm J. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost 2007;5:692-9. (Pubitemid 46563566)
-
(2007)
Journal of Thrombosis and Haemostasis
, vol.5
, Issue.4
, pp. 692-699
-
-
Naess, I.A.1
Christiansen, S.C.2
Romundstad, P.3
Cannegieter, S.C.4
Rosendaal, F.R.5
Hammerstrom, J.6
-
4
-
-
84880327613
-
Oral apixaban for the treatment of acute venous thromboembolism
-
Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013;369:799-808.
-
(2013)
N Engl J Med
, vol.369
, pp. 799-808
-
-
Agnelli, G.1
Buller, H.R.2
Cohen, A.3
-
5
-
-
71849117615
-
Dabigatran versus warfarin in the treatment of acute venous thromboembolism
-
Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009;361:2342-52.
-
(2009)
N Engl J Med
, vol.361
, pp. 2342-2352
-
-
Schulman, S.1
Kearon, C.2
Kakkar, A.K.3
-
6
-
-
78650619315
-
Oral rivaroxaban for symptomatic venous thromboembolism
-
The EINSTEIN Investigators
-
The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010;363:2499-510.
-
(2010)
N Engl J Med
, vol.363
, pp. 2499-2510
-
-
-
7
-
-
84859385808
-
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism
-
The EINSTEIN-PE Investigators
-
The EINSTEIN-PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012;366:1287-97.
-
(2012)
N Engl J Med
, vol.366
, pp. 1287-1297
-
-
-
8
-
-
84868662780
-
National trends in oral anticoagulant use in the United States, 2007 to 2011
-
Kirley K, Qato DM, Kornfield R, Stafford RS, Alexander GC. National trends in oral anticoagulant use in the United States, 2007 to 2011. Circ Cardiovasc Qual Outcomes 2012;5:615-21.
-
(2012)
Circ Cardiovasc Qual Outcomes
, vol.5
, pp. 615-621
-
-
Kirley, K.1
Qato, D.M.2
Kornfield, R.3
Stafford, R.S.4
Alexander, G.C.5
-
9
-
-
81055155535
-
Warfarin dose assessment every 4 weeks versus every 12 weeks in patients with stable international normalized ratios: A randomized trial
-
Schulman S, Parpia S, Stewart C, Rudd-Scott L, Julian JA, Levine M. Warfarin dose assessment every 4 weeks versus every 12 weeks in patients with stable international normalized ratios: a randomized trial. Ann Intern Med 2011;155:653-9.
-
(2011)
Ann Intern Med
, vol.155
, pp. 653-659
-
-
Schulman, S.1
Parpia, S.2
Stewart, C.3
Rudd-Scott, L.4
Julian, J.A.5
Levine, M.6
-
10
-
-
78349294600
-
Statistical design of personalized medicine interventions: The Clarification of Optimal Anticoagulation through Genetics (COAG) trial
-
French B, Joo J, Geller NL, et al. Statistical design of personalized medicine interventions: the Clarification of Optimal Anticoagulation through Genetics (COAG) trial. Trials 2010;11:108.
-
(2010)
Trials
, vol.11
, pp. 108
-
-
French, B.1
Joo, J.2
Geller, N.L.3
|